Etanercept is a Fusion Protein owned by Amgen, and is involved in 92 clinical trials, of which 87 were completed, and 5 are ongoing.
Etanercept is a human tumor necrosis factor receptor p75 fc fusion protein produced by recombinant DNA technology in a chinese hamster ovary (CHO) mammalian cell expressing system. Etanercept inhibits binding of both TNF alpha and TNF beta (lymphotoxin alpha [LT aplha]) to cell surface TNFRs, rendering TNF biologically inactive.
The revenue for Etanercept is expected to reach a total of $10.6bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Etanercept NPV Report.
Etanercept (Enbrel, Enbrel PFS) is a dimeric fusion protein, immunomodulator and an antirheumatic agent. It is formulated as solution and powder for solution for subcutaneous route of administration. It is indicated for the treatment of moderate to severe active rheumatoid arthritis, polyarticular juvenile idiopathic arthritis (JIA) in patients ages 2 and older and active ankylosing spondylitis (AS). It is also indicated for reducing signs and symptoms, inhibiting the progression of structural damage of active arthritis, and improving physical function in patients with psoriatic arthritis (PsA). Enbrel can be used with or without methotrexate(MTX) in the treatment of psoriatic arthritis. In addition, it is also used for the treatment of adult patients (18 years or older) with chronic moderate to severe plaque psoriasis (PsO) who are candidates for systemic therapy or phototherapy and plaque psoriasis in pediatric patients. Enbrel for pediatric use injection is only used for juvenile idiopathic arthritis and pediatric plaque psoriasis. Enbrel is indicated for the treatment of patients 4 to 17 years with chronic moderate to severe plaque psoriasis (PsO) who are candidates for systemic therapy or phototherapy. It is also indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (jia) in patients aged 4 to 17 years who have had an inadequate response to one or more disease-modifying antirheumatic drugs (DMARDs). Enbrel has not been studied in children less than 2 years of age. It is indicated for the treatment of non-radiographic axial spondyloarthritis.
The drug candidate is under development as a monotherapy for psoriatic arthritis and in maintaining remission of rheumatoid arthritis. It was also under development for the treatment of Wegener's granulomatosis and hidradenitis suppurativa.
It was under development for the treatment of palmoplantar pustulosis.
Pfizer discovers, develops, manufactures and commercializes biopharmaceuticals. The company offers products to treat various conditions such as cardiovascular, metabolic and pain, cancer, inflammation, immune disorders and rare diseases. It also provides sterile injectable pharmaceuticals, biosimilars, active pharmaceutical ingredients (APIs) and contract manufacturing services. Pfizer sells its products through wholesalers, retailers, hospitals, clinics, government agencies and pharmacies. It has major manufacturing facilities in India, China, Japan, Ireland, Italy, Belgium, Germany, Singapore, and the US. The company provides its products in North America, South America, Asia-Pacific, Australia, Europe, Africa and the Middle East. Pfizer is headquartered in New York, the US.
The company reported revenues of (US Dollars) US$81,288 million for the fiscal year ended December 2021 (FY2021), an increase of 95.2% over FY2020. In FY2021, the company’s operating margin was 29.1%, compared to an operating margin of 18.8% in FY2020. In FY2021, the company recorded a net margin of 27%, compared to a net margin of 22% in FY2020.
Quick View – Etanercept
|Highest Development Stage|